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The authors regret to inform that there was an inadvertent error in
the section of “2.1. Experimental autoimmune encephalomyelitis (EAE)
induction” and the correct text is provided below:
Ten-week-old female C57BL/6 mice were purchased from the
Pasteur Institute (Tehran, Iran). All animals were kept in a sterile fa-
cility according to the Guidelines of the Iran University of Medical
Science. All animal procedures were in accordance with the Ethics
Committee of the Iran University of Medical Science
(IR.IUMS.FMD.REC 1396.9321540002). The EAE model was provided
by “Salari Institute of Cognitive and Behavioral Disorders (SICBD)”. To
this aim, the animals were anesthetized by the intraperitoneal
administration of ketamine and xylazine. Then, 300 µg of Myelin
Oligodendrocyte Glycoprotein (MOG35–55; SICBD) peptide was emul-
sified with complete Freund′s adjuvant (500 µg Mycobacterium tu-
berculosis; CFA; Sigma, F5881, USA) and subcutaneously injected into
both hind flanks of each mouse. All mice received two doses of 0.3 µg
pertussis toxin (List Biological Lab, Campbell, CA, USA) through the
intraperitoneal (i.p.) injection about two hours and forty-eight hours
after immunization.
All authors are aware of the errors and have agreed to the correc-
tion. The authors would also like to apologise for any inconvenience
caused.
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